GSK buys respiratory drug maker Aiolos for $1bn
9th Jan 2024 07:16
(Sharecast News) - GSK said it was buying Aiolos, a clinical-stage biopharmaceutical company focused on treatment of respiratory and inflammatory conditions, for up to $1.4bn (£1.1bn).
Read moreLondon close: Stocks fall amid rising geopolitical concerns
3rd Jan 2024 17:48
(Sharecast News) - London stocks closed lower on Wednesday - the 40th anniversary of the FTSE 100's launch - as sentiment remained cautious due to increasing tensions in the Middle East.
Read moreJefferies upgrades GSK to 'buy', cuts AstraZeneca to 'hold'
3rd Jan 2024 11:07
(Sharecast News) - Jefferies has upgraded its rating on GlaxoSmithKline to 'buy' and cut AstraZeneca to 'hold' as part of its review of the European pharma sector.
Read moreGSK buys rights to Hansoh Pharma antibody-drug conjugate
20th Dec 2023 13:29
(Sharecast News) - GSK has agreed to buy the rights to an antibody-drug conjugate (ADC) - HS-20093 - from Chinese biopharmaceutical group Hansoh Pharma.
Read moreGSK sees success in Jemperli endometrial cancer trial
18th Dec 2023 07:18
(Sharecast News) - GSK released positive headline results from the planned analysis of its trial of Jemperli in endometrial cancer on Monday.
Read moreGSK seeks to extend RSV vaccine approval in Japan
12th Dec 2023 07:24
(Sharecast News) - GSK announced on Tuesday that Japan's Ministry of Health, Labour and Welfare (MHLW) has accepted its regulatory application for the extension of the indication of its RSV vaccine to include adults aged 50- to 59 at an increased risk of contracting the disease.
Read moreGSK endometrial cancer treatment gets Europe authorisation
11th Dec 2023 07:23
(Sharecast News) - GSK announced on Monday that the European Commission has granted marketing authorisation for 'Jemperli', or dostarlimab, in combination with chemotherapy for certain endometrial cancers.
Read moreGSK receives 'positive' headline results from phase III trial
27th Nov 2023 08:02
(Sharecast News) - Drugmaker GSK announced on Monday that it had received positive headline results from a planned interim efficacy analysis from a phase III trial evaluating its elantamab mafodotin asset.
Read moreLondon close: Stocks rise ahead of US Fed policy decision
1st Nov 2023 16:35
(Sharecast News) - London's stock market finished in positive territory on Wednesday, with investors keeping a keen eye on the upcoming policy announcement from the US Federal Reserve.
Read moreGSK hikes guidance after strong third quarter
1st Nov 2023 07:27
(Sharecast News) - GSK announced a robust third quarter on Wednesday, prompting an upgrade to its full-year guidance.
Read moreGSK's Jemperli sees success in endometrial cancer trial
30th Oct 2023 07:06
(Sharecast News) - GSK reported encouraging outcomes from part one of the 'RUBY' phase three trial evaluating the efficacy of 'Jemperli', or dostarlimab, with standard chemotherapy for treating adult patients with advanced or recurrent endometrial cancer on Monday.
Read moreGSK HIV injection regimen gets approval in China
26th Oct 2023 07:02
(Sharecast News) - GSK announced on Thursday that its majority-owned HIV specialist subsidiary ViiV has received approval from the National Medical Products Administration (NMPA) of China for an injection regimen.
Read moreGSK hails success in US RSV vaccine trial
25th Oct 2023 07:27
(Sharecast News) - Pharma giant GSK has announced positive preliminary results from a trial of its Arexvy vaccine to treatment respiratory syncytial virus (RSV) disease for a younger patient population in the US.
Read moreGSK nears green light for Jemperli usage in Europe
16th Oct 2023 07:16
(Sharecast News) - Pharma giant GSK has announced that European experts recommended the approval of its Jerperli drug for the treatment of a specific type of endometrial cancer - paving the way for marketing authorisation by the continent's regulatory body.
Read moreGSK settles California Zantac lawsuit
11th Oct 2023 11:51
(Sharecast News) - GSK has agreed to settle another lawsuit concerning its discontinued heartburn treatment Zantac, the drugs giant confirmed on Wednesday.
Read more